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Background: It is important to continually reevaluate the risk/benefit calculus of internal mammary node
irradiation (IMNI) in the era of modern systemic therapy. We aimed to investigate the effect of IMNI on
survival in node-positive breast cancer treated with mastectomy and anthracycline plus taxane-based
chemotherapy.
Methods: We analyzed 348 patients who underwent mastectomy and anthracycline plus taxane-based
chemotherapy for node-positive breast cancer between January 2006 and December 2011. All patients
received postoperative radiation therapy (RT) with IMNI (n ¼ 105, 30.2%) or without IMNI (n ¼ 243,
69.8%). The benefit of IMNI for disease-free survival (DFS) and overall survival (OS) was evaluated using
multivariate analysis and inverse probability of treatment weighting (IPTW) to adjust for unbalanced
covariates between the groups.
Results: After a median follow-up of 95 months, the 10-year locoregional recurrence-free survival rate,
DFS, and OS in all patients were 94.8%, 77.4%, and 86.2%, respectively. The IPTW-adjusted hazard ratio
(HR) for the association of IMNI (vs. no IMNI) with DFS and OS was 0.208 (95% confidence intervals (CI)
0.045e0.966) and 0.460 (95% CI, 0.220e0.962), respectively. In multivariate analysis, IMNI was a favor-
able factor for DFS (HR, 0.458; P ¼ 0.021) and OS (HR 0.233, P ¼ 0.018).
Conclusions: IMNI was associated with improved DFS and OS in node-positive patients treated with
mastectomy, post-mastectomy RT, and taxane-based chemotherapy, although the rate of locoregional
recurrence was low.
© 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The benefit of post-mastectomy radiation therapy (PMRT) in
node-positive breast cancer has been established in several ran-
domized trials [1e4]. In these previous studies, PMRT consisted ofOncology, Samsung Medical
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an open access article under the Cchest wall and comprehensive regional nodal irradiation (RNI). The
European Organization for Research and Treatment of Cancer
(EORTC) 22922 and MA 20 trials recently demonstrated the benefit
of RNI on the rate of distant metastases as well as locoregional
recurrence in positive axillary lymph node (LN) or high risk, node-
negative breast cancer [5,6]. Although comprehensive inclusion of
axillary LN, supraclavicular node (SCN), and internal mammary
node (IMN) are recommended in international guidelines, there is
significant inter-physician variability in real-world practice, espe-
cially in IMN as IMN irradiation can increase doses to the heart and
lungs [7e9].
During the past decades, there have been several important
advances in the field of systemic treatments for breast cancer. The
use of taxane-based chemotherapy, in addition to anthracyclin-
based chemotherapy, was proven to improve survival in breastC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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therapy for node-positive breast cancer [10e12]. The advent of
anti-HER2 target agents has revolutionized the treatment of HER2-
positive disease with improved survival [13]. Whether applying
RNI, specifically irradiating IMN, can provide the same benefit
shown in the EORTC 22022 (1996e2004) and MA 20 (2000e2007)
trials in the context of modern adjuvant therapies including
anthracycline/taxane-based chemotherapy and anti-HER2 therapy,
which were not administered in these studies, is a clinically rele-
vant question.
We previously reported retrospective studies investigating the
role of IMNI in the 1990s cohort (mostly received cyclophospha-
mide, methotrexate, and fluorouracil (CMF) chemotherapy) and the
2000s cohort (in the setting of preoperative systemic therapy)
[14,15]. In this study, we aimed to investigate the effect of IMNI in
patients who received PMRT and adjuvant modern systemic ther-
apy for node-positive breast cancer.2. Materials and methods
2.1. Patients
This study was approved by the Institutional Review Board at
the Samsung Medical Center and Yonsei Cancer Center, and
informed consent was waived. From January 2006 to December
2011, we identified 348 patients diagnosed with node-positive
breast cancer who underwent a mastectomy followed by adju-
vant taxane-based chemotherapy and radiation therapy (RT). We
excluded patients who had clinical involvement of IMN or SCN, did
not receive taxane-based chemotherapy, underwent preoperative
systemic therapy, or had a history of previous or concurrent ma-
lignancy, including contralateral breast cancer.2.2. Treatment
All patients underwent amastectomy, followed by taxane-based
adjuvant chemotherapy. The most common regimen was four cy-
cles of anthracycline and cyclophosphamide (AC), followed by four
cycles of taxane (T) (n ¼ 234, 67.2%), followed by eight cycles of
anthracycline plus taxane (AT) (n¼ 103, 29.6%). Adjuvant endocrine
therapy was administered to 98.5% (269/273) of estrogen receptor
(ER)-positive or progesterone receptor (PR)-positive patients, and
targeted therapy was administered to 85.0% (68/80) of the HER2-
positive patients. For axillary management, 345 (99.1%) patients
underwent axillary LN dissection, and three (0.9%) patients un-
derwent sentinel LN biopsy only. The median number of dissected
LNs was 22 (range, 3e59). PMRTwas indicated in patients with pN2
and high risk N1 [16e18]. Irradiation to the ipsilateral SCN was
performed in 328 (94.3%) patients, and the median radiation dose
to the chest wall and SCN was 50.4 Gy (range, 45e54 Gy) with
1.8.2.0 Gy per fraction. IMNI was performed based on the physi-
cian's discretion, as described in previous studies [14,15]. Computed
tomography-based treatment planning and three-dimensional
conformal RT were used in all patients. The ipsilateral IMN area,
including the 1st to 3rd intercostal space, was delineated for IMN
treatment. In the no IMNI group, two tangential photon beam fields
for the chest wall and a single anterior photon beam field for the
SCNs were used with a single isocenter. In the IMNI group, the SCN
and lateral chest wall were treated by the photon beam reverse
hockey stick field, and the IMN and medial chest wall were treated
by an anterior electron beam field. An individual custom-made step
bolus and reverse hockey stick technique were used to compensate
for differences in chest wall thickness to reduce the irradiation dose
to the lung/heart. The heart block was not routinely applied.382.3. Analysis
The characteristics according to IMNI, were compared using c2
or Fisher's exact test. To minimize the effects of imbalanced base-
line characteristics between the groups, the propensity score in-
verse probability of treatment weighting (IPTW) was used.
Propensity scores were calculated using a multivariate logistic
regression model, including laterality (left vs. right), grade (III vs.
III), T stage (T1 vs. T2 vs. T3eT4), and N stage (N1 vs. N2 vs. N3).
Each patient was then assigned an estimated propensity score
based on the patient's baseline characteristics.
Disease-free survival (DFS) was defined as the time from surgery
to any recurrence or death, and overall survival (OS) was defined as
the time from surgery to death from any cause. DFS and OS rates
were estimated using the Kaplan-Meier method and compared
using log-rank tests, and IPTW-adjusted Kaplan-Meier curves were
also estimated. Local recurrence was defined as disease recurrence
within the ipsilateral chest wall, and regional recurrence was
defined as recurrence within the axillary, supraclavicular, or inter-
nal mammary LNs. Any symptomatic event after irradiation was
investigated to evaluate the pulmonary and cardiac toxicities. Ra-
diation pneumonitis was graded using common terminology
criteria for adverse events version 5.0. Any cardiac toxicities
included coronary artery disease, cardiomyopathy, pericardial dis-
ease, and conduction abnormalities. Cox proportional hazards
regression models in univariate and multivariate analyses for all
patients to calculate adjusted hazard ratios (HRs) and 95.0% con-
fidence intervals (CIs). A p-value of less than 0.05 was considered
statistically significant. All statistical analyses were performed us-
ing R version 4.0.2 (The R Foundation for Statistical Computing,
Vienna, Austria) and SPSS Statistics version 20 (IBM, USA).
3. Results
3.1. Patient characteristics
The median age of all patients was 47 years (range, 27e74
years). Of all patients, 105 (30.2%) patients received IMNI and 243
(69.8%) did not. Patient characteristics, according to IMNI before
and after IPTW, are described in Table 1. Before applying IPTW,
patients in the no IMNI group had left breast cancer and unfavor-
able factors more frequently, including grade III, advanced pT stage,
and advanced pN stage, than those in the IMNI group. Other char-
acteristics, including age, menopausal status, location, and ER, PR,
and HER2-positivity, were evenly distributed between the groups.
After applying IPTW, the distribution of variables between the
groups attained a reasonable balance.
3.2. Survival
During the median follow-up of 95 months (range, 4e141
months), 66 patients experienced recurrence and 34 patients died
of disease progression (n ¼ 32) or without disease (n ¼ 2). For the
whole cohort, DFS and OSwere 83.8% and 93.2% at 5-year and 77.4%
and 86.2% at 10-year, respectively. In univariate analysis, the IMNI
group showed better DFS (79.9% and 92.4% at 5 years, HR 0.370 [95%
CI 0.193e0.710], P ¼ 0.002) and OS (90.5% vs. 99.0% at 5 years, HR
0.178 [95% CI 0.054e0.584], P ¼ 0.001) compared to the no IMNI
group. In a multivariate analysis for the unadjusted cohort, IMNI
remained as a significant factor for DFS (HR, 0.458, 95% CI
0.235e0.891, P ¼ 0.021) and OS (HR 0.233, 95% CI 0.070e0.778,
P¼ 0.018, Table 2). In addition to IMNI, advanced pT stage (pT3eT4,
HR 1.727, 95% CI 1.021e2.920, P ¼ 0.042) and advanced pN stage
(pN3, HR 2.666, 95% CI 1.602e4.438, P < 0.001) were unfavorable
factors for DFS, and advanced pN stage (pN3, HR 2.313, 95% CI
Table 1
Patient characteristics by internal mammary node irradiation before and after using inverse probability treatment weighting method.
Characteristics Before IPTW After IPTW







































































































































































































































IMNI, internal mammary node irradiation; ER, estrogen receptor; PR, progesterone receptor.
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multivariate analysis. In the IPTW-adjusted cohort, IMNI was also
associated with improved DFS (HR 0.420, 95% CI 0.045e0.966,
P ¼ 0.036) and OS (HR 0.208, 95% CI 0.045e0.966, P ¼ 0.014),
respectively (Fig. 1).3.3. Patterns of failure
Table 3 shows the first relapse site according to the IMNI. The
most common failure was distant recurrence (61 patients, 17.5%) in
all patients. The rate of distant recurrence was higher in the no
IMNI group (21.0% vs. 9.5%, P ¼ 0.010), and regional recurrence was
higher in the no IMNI group (5.8% vs. 1.9%, P ¼ 0.115). In the IMNI39group, there was no IMN recurrence, while four patients developed
IMN recurrence in the no IMNI group. Patterns of failure in the
IPTW-adjusted cohort revealed that the regional recurrence rate
was higher in the no IMNI group than in the IMNI group (5.6% vs.
1.4%, P ¼ 0.035, Table 3).3.4. Toxicities
Grade 1e2 radiation pneumonitis was observed in six patients,
and cardiac toxicities developed in nine patients after radiation.
Therewas no significant difference in toxicities between the groups
(Table 4).
Table 2
Multivariate analysis for disease-free survival and overall survival in the unadjusted
cohort.
Characteristics Disease-free survival Overall survival
HR (95% CI) P value HR (95% CI) P value
IMNI
No 1 1
Yes 0.458 (0.235e0.891) 0.021 0.233 (0.070e0.778) 0.018
Age
<50 1 1
S50 0.921 (0.533e1.592) 0.768 1.020 (0.478e2.174) 0.960
Laterality
Left 1 1
Right 0.972 (0.594e1.592) 0.911 0.977 (0.490e1.946) 0.946
Location
Inner/central 1 1
Outer 0.944 (0.568e1.567) 0.823 0.880 (0.429e1.809) 0.729
Grade
I-II 1 1
III 1.056 (0.616e1.812) 0.843 1.134 (0.526e2.447) 0.748
pT stage
pT1-2 1 1
pT3-4 1.727 (1.021e2.920) 0.042 1.974 (0.960e4.056) 0.064
pN stage
pN1-2 1 1
pN3 2.666 (1.602e4.438) <0.001 2.313 (1.134e4.716) 0.021
ER
Negative 1 1
Positive 0.381 (0.114e1.269) 0.116 0.222 (0.047e1.060) 0.059
PR
Negative 1 1
Positive 1.789 (0.555e5.771) 0.330 1.306 (0.275e6.191) 0.737
Her2
Negative 1 1
Positive 0.676 (0.348e1.311) 0.247 0.628 (0.263e1.502) 0.296
HR, hazard ratio; CI, confidence interval; IMNI, internal mammary node irradiation;
ER, estrogen receptor; PR, progesterone receptor.
Fig. 1. Disease-free survival and overall survival with or without internal mammary node irr
Table 3
Patterns of failure in the unadjusted cohort.
No IMNI IMNI P value
Patterns of failure in the unadjusted cohort
Local 2 (0.8%) 2 (1.9%) 0.385




Axilla & SCN 3 0
SCN & IMN 1 0
DM 51 (21.0%) 10 (9.5%) 0.010
LRR only 2 (0.8%) 1 (1.0%) 0.082
DM only 39 (16.0%) 8 (7.6%)
LRR þ DM 12 (4.9%) 2 (1.9%)
Death 31 (12.8%) 3 (2.9%) 0.004
Death without disease 2 0
Patterns of failure in the inverse probability treatment weighting-adjusted
cohort
Local 2.0 (0.8%) 3.4 (2.3%) 0.254
Regional 14.7 (5.6%) 2.1 (1.4%) 0.035
DM 49.6 (18.8%) 16.2 (11.1%) 0.034
IMNI, internal mammary node irradiation; SCN, supraclavicular node; IMN, internal
mamary node; LRR, locoregional recurrence; DM, distant metastasis.
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403.5. Subgroup analysis
The effect of IMNI was evaluated in various subgroups including
menopausal status, laterality, location, grade, pT stage, pN stage,
and ER, PR, and HER2-positivity. The effect of IMNI on DFS was
more evident in premenopausal women (HR, 0.269, 95% CI
0.113e0.641, P¼ 0.003), pT2 disease (HR 0.296, 95% CI 0.102e0.858,
P ¼ 0.025), pN2 disease (HR 0.116, 95% CI 0.015e0.875, P ¼ 0.037),
grade III (HR 0.199, 95% CI 0.047e0.839, P ¼ 0.028), ER-positive (HRadiation in adjusted cohorts using the inverse probability treatment weighting method.
Table 4
Toxicities.
No IMNI IMNI p value
Grade 1e2 Radiation pneumonitis 4 (1.6%) 2 (1.9%) 0.865
Any cardiac toxicities 6 (2.5%) 3 (2.9%) 0.834
IMNI, internal mammary node irradiation.
W.K. Cho, J.S. Chang, S.G. Park et al. The Breast 59 (2021) 37e430.301, 95% CI 0.140e0.648, P¼ 0.002), PR-positive (HR 0.349, 95% CI
0.163e0.748, P ¼ 0.007), and HER2-negative patients (HR 0.410,
95% CI 0.204e0.823, P ¼ 0.012, Fig. 2).
4. Discussion
In our study, we sought to explore whether the benefit of IMNI
observed in EORTC22922/MA20 trials also applies to breast cancer
patients treated with modern chemotherapy, including taxane-
based chemotherapy and/or anti-HER2-targeted therapies. Unlike
other retrospective studies in which IMNI was applied to patients
with a higher risk [19,20], the IMNI group of this study included less
advanced tumors than the no IMNI group. This imbalance is pri-
marily attributable to the different policies between the physicians,
one of whom treated IMNs in all RNI cases while the other physi-
cian treated IMNs only when the tumor was involved. To assess the
independent effect of IMNI with our imbalanced retrospective data,
we conducted a Cox proportional multivariate analysis and an
IPTW-adjusted analysis. Even after adjustment for imbalanced
factors, IMNI was a significant factor for higher DFS and OS.
After the final reports of MA 20 and the EORTC trial demon-
strated the benefit of comprehensive nodal irradiation, guidelinesFig. 2. Hazard ratio of internal mammary node irradiat
41and patterns of practice have changed toward supporting its
routine use [21]. However, these trials did not determine whether
IMNI specifically contributed to the survival benefit. The first ran-
domized trial to assess the role of IMNI, which was initiated by the
French group in 1991, was published in 2013 and showed no sta-
tistical differences in 10-year OS between IMNI and no IMNI [22].
Second, the DBCG-IMN study, a prospective, population-based
cohort study in Denmark, reported a statistically significant
improvement in 8-year OS with IMNI (HR, 0.82) [23]. Recently, a
multi-center prospective trial (KROG 08e06), which randomly
assigned 747 patients to the IMNI or no IMNI group was presented
in the 2020 annual meeting of the Korean Society for Radiation
Oncology, and found that the increase in 7-year DFS (IMNI vs. no
IMNI, 85% vs. 82%) was not statistically significant and the pre-
defined endpoint (10% difference) was not reached [24].
These conflicting data can be explained by the incidental doses
of IMN in the no IMNI group and the insufficient doses in the IMNI
group in each study. In the quality assurance (QA) study of KROG
08e06, 37% of the patients in the no IMNI group received 60% or
more of the prescribed dose, and only 53% of the patients in the
IMNI group received the recommended dose of the IMNI [25]. In the
French trial, treatment planning was two-dimensional, and quality
control was lacking.Without a rigorous RT QA program, it would be
difficult to detect the effect of IMNI in multi-center trials. In DBCG-
IMN, although not randomly assigned, patients were recommended
to undergo IMNI in right-sided tumors and were recommended not
to receive IMNI in left-sided tumors as per national guidelines,
based on the presumption of potentially increased heart toxicity by
IMNI in left-sided tumors. In this context, we speculated that the
consistent discrepancy in the RT technique and indication betweenion on disease-free survival in different subgroups.
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[14,15] more similar to those from the DBCG-IMN study.
The serial reports of our group demonstrated an improvement
in survival outcomes over the study period (10-year DFS 61%, 70%,
and 77% in the study by Chang et al. Kim et al. and this study,
respectively) [14,15], which probably reflects the benefit of
advanced systemic treatment (Supplementary Fig. 1). Compared to
the DBCG-IMN study, the OS rate in our study was much higher
(86.2% at 10 years vs. 72.2e75.9% at 8 years), even though our
cohort included more advanced N stage (pN2, 82% vs. 40%).
Although there are concerns about the possible diminished role of
RT in the context of modern chemotherapy [26], we found that the
contribution of IMNI to DFS was higher, or at least similar in the
current study (HR 0.46) than in our previous studies (HR 0.58e0.70,
Supplementary Table 1) [14,15]. This may be in linewith the lessons
of the EBCTCG analysis, which showed that the effect of locore-
gional control on survival is higher under effective systemic treat-
ment and modern RT [27].
The benefit of IMNI was more evident in premenopausal, pT2
disease, pN2 disease, and grade III, ER-positive, PR-positive, and
HER2-negative disease. This is similar to the DBCG-IMN study,
which showed that the benefit of IMNIwasmore pronounced in the
pN2 and premenopausal subgroup [23]. Our group also previously
reported that the benefit of IMNI was the most obvious in pN2
patients [15]. Interestingly, ER-positive, PR-positive, and HER2-
negative patients showed a higher benefit of IMNI, which is
similar to a study byWang et al. [20]. They investigated the effect of
IMNI in 872 patients treated with breast-conserving surgery or
mastectomy in the modern systemic treatment era. They also
showed that IMNI improved both DFS and OS even after propensity
score matching. Our results, together with these previous studies,
support the selective use of IMNI for patients at high risk of
recurrence.
One of the major concerns regarding IMNI is that pulmonary
and cardiac toxicities could offset the effect of IMNI. In our study,
IMNI did not increase the incidence of adverse events. We used an
electron beam with an individualized custom-made step bolus for
the IMN and medial chest wall irradiation in the IMNI group, which
might reduce lung and cardiac toxicities. Less lifestyle-associated
risk factors and younger age at cancer diagnosis of Asian women
might have attributed to less risk of radiation-related cardiac
toxicity [28,29]. Previous studies in the Korean population reported
that the incidence of coronary events did not differ between
women treated with RT for left and right breast cancer, and the risk
of cardiac-related death did not differ between breast cancer sur-
vivors and the general population [30,31]. Advances in cardiac-
sparing RT techniques, including deep inspiration breath hold,
prone, proton, and/or IMRT, which were not used in this study,
might further reduce the risk of cardiac and lung toxicities [32].
Continued efforts to reduce RT-related toxicities will be needed to
maximize the benefit of IMNI bywidening the therapeutic window.
This study has several limitations. First, the baseline character-
istics between the IMNI and no IMNI groups were imbalanced.
Although we conducted a multivariate analysis, bias may still exist
because of the retrospective nature of this study. Possible under-
reporting of late cardiac and pulmonary toxicities is another limi-
tation of this study. Nevertheless, this study included a large
number of patients treated with protocol-based planning, which
would have minimal variation in RT dose distribution.
In conclusion, our study suggests that IMNI has a statistically
significant impact on DFS and OS in node-positive breast cancer
patients treated with mastectomy, axillary LN dissection, PMRT,
and taxane-based chemotherapy, although the rate of locoregional
recurrence in this population is very low. Given that modern sys-
temic therapies dramatically impact the risk of locoregional42recurrence and modern RT techniques can substantially reduce
heart/lung doses, the risk/benefit calculus of IMNI should be
continually reevaluated.
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